Sneag Darryl B, Schaaf H Simon, Cotton Mark F, Zar Heather J
Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA.
Pediatr Infect Dis J. 2007 Dec;26(12):1142-6. doi: 10.1097/INF.0b013e31814523e4.
There is little published information on optimal chemoprophylaxis for children with multidrug-resistant tuberculosis (MDR-TB) contacts. Current guidelines of World Health Organization suggest that isoniazid (INH), the standard first-line chemoprophylaxis, be used for those exposed to MDR-TB.
This is a retrospective review of medical records of 5 children residing in the Western Cape Province, South Africa, who developed MDR-TB while receiving conventional chemoprophylaxis with either INH or a combination of INH, rifampin, and pyrazinamide.
Adult MDR-TB source cases were identified for all children and resistance patterns of patient and source case isolates matched in all cases. The median age of the patients was 0.4 years. One patient participated in a trial of INH chemoprophylaxis for HIV-infected children. Four HIV-uninfected infants presented with TB-related symptoms several months after being given chemoprophylaxis because of a known source case. Stigmata of TB were cough >3 weeks in 4, weight loss or a history of failing to thrive in 3, fever in 2 infants, and reported night sweats in 1. Chest radiographs at diagnosis revealed lymphadenopathy, lobar opacification, and airway narrowing. All patients were treated for varying time periods at a TB referral institution in the Western Cape.
Standard, first-line anti-TB agents were inadequate to prevent MDR-TB in children exposed to MDR-TB contacts. Second-line chemoprophylaxis, reflecting the susceptibility profile of the source case's isolate, with at least 2 drugs with activity against the drug-resistant isolate for 6-12 months should be considered.
关于耐多药结核病(MDR-TB)接触儿童的最佳化学预防,公开的信息很少。世界卫生组织目前的指南建议,标准的一线化学预防药物异烟肼(INH)应用于接触MDR-TB的人群。
这是一项对居住在南非西开普省的5名儿童的病历进行的回顾性研究,这些儿童在接受INH或INH、利福平及吡嗪酰胺联合常规化学预防时发生了MDR-TB。
所有儿童均确定了成人MDR-TB传染源,且所有病例中患者和传染源分离株的耐药模式均匹配。患者的中位年龄为0.4岁。1名患者参与了一项针对HIV感染儿童的INH化学预防试验。4名未感染HIV的婴儿在因已知传染源而接受化学预防数月后出现了与结核病相关的症状。结核病的体征包括4例咳嗽超过3周、3例体重减轻或发育不良史、2例婴儿发热以及1例盗汗。诊断时的胸部X光片显示有淋巴结病、肺叶实变和气道狭窄。所有患者均在西开普省的一家结核病转诊机构接受了不同时间段的治疗。
标准的一线抗结核药物不足以预防接触MDR-TB的儿童发生MDR-TB。应考虑采用二线化学预防,根据传染源分离株的药敏情况,使用至少2种对耐药分离株有活性的药物,持续6至12个月。